Cathie Wood’s Stock Portfolio: 2025 Stock Picks

13. Twist Bioscience Corporation (NASDAQ:TWST)

ARK Investment Management’s Q3 Stake Value: $242 million

Number of Hedge Fund Holders: 24

Twist Bioscience Corporation (NASDAQ:TWST) is a synthetic biology startup that provides genetic testing upstream. Unlike other companies that manufacture medications and genetic testing products, the company supplies raw materials to the industry. The company also plans to industrialize biological engineering by developing a platform that synthesizes DNA on silicon rather than traditional, well-plastic plates. This platform makes use of a proprietary semiconductor-based synthetic DNA manufacturing process to generate high-quality synthetic DNA more quickly and affordably.

Twist Bioscience’s fiscal year 2024 ended on a relatively high note, with Q4 revenues up 27% to $84.7 million and annual revenue up 28% to $330 million. Additionally, according to the company’s preliminary FY25 guidance, the Next Generation Sequencing (NGS) and Synthetic Biology (SynBio) sectors will account for much of the projected year-over-year revenue growth.

Baird reaffirmed its bullish outlook for Twist Bioscience Corporation (NASDAQ:TWST) back in December, maintaining an Outperform rating and a $48 price target. The firm’s observations were based on Twist Bioscience’s Express Genes pricing premiums, which were tracked on a daily basis. The goal of this tracking is to determine how much demand exists for the company’s synthetic gene services. The observed premiums suggest that the company’s products are in high demand, especially in business and academia. Baird stated that while higher pricing premiums could be viewed positively, they were hesitant to apply the data directly to Twist Bioscience’s total revenue or gross margin percentages.